Week In Review: China Green Lights Nasdaq-Style Exchange For Young Companies

China has given the green light to a new registration-based Shanghai stock exchange aimed at high tech companies that, apparently, will be less regulated than other China exchanges (see story). The new exchange is described as resembling Nasdaq with its dealer-to-dealer pricing mechanism. Presumably, the new exchange will allow pre-profit high-tech China companies to raise capital, taking some of the listings from Hong Kong's new IPO rules for young companies. Hong Kong requires pre-profit biopharmas to have products in late-stage development. So far, China has not specified the requirements for companies seeking to IPO on the new Shanghai exchange.  

Deals and Financings

iKang Healthcare (Nasdaq: KANG), a private China healthcare chain, completed a $1.4 billion privatization backed by an Alibaba (NYSE: BABA) investment arm and Yunfeng Capital, a private equity firm co-founded by Alibaba's Jack Ma and David Yu (see story). The company, which seems likely to become part of Alibaba Health, offers check-ups and disease screening. The privatization was completed at a price of $20.60 per ADS. iKang staged a $153 million IPO in 2014 and proposed a privatization 16 months later. It has taken three and a half years to complete the transaction.

Circassia Pharma (LSE: CIR), an Oxford UK respiratory disease company, entered a $32.7 million agreement to acquire US and China marketing rights for AirNOvent, a nitric oxide product developed by US-based AIT Therapeutics (see story). AirNOvent is a ventilator compatible nitric oxide product that is administered for respiratory failure associated with persistent pulmonary hypertension of newborns (PPHN). AIT, which also intends to seeks a second indication for AirNOvent, expects to apply for US approval of the product in Q2 2019, with a market launch in 2020.

Immunochina Pharma of Beijing has closed a $20.4 million Series C financing to advance its CAR-T candidates (see story). The company will expand its GMP-grade manufacturing capabilities and continue clinical trials of its lead IM19 molecule, a CD19 CAR-T immunotherapy. in patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Non Hodgkin’s Lymphoma. Immunochina increased the size of the C financing after it presented strong results for its lead CAR-T molecule at the ASH conference in December. 

1 2
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.